135 related articles for article (PubMed ID: 31630355)
1. Cross-talk between ribosome biogenesis, translation, and mTOR in CD133+ 4/CD44+ prostate cancer stem cells.
Binal Z; Açıkgöz E; Kızılay F; Öktem G; Altay B
Clin Transl Oncol; 2020 Jul; 22(7):1040-1048. PubMed ID: 31630355
[TBL] [Abstract][Full Text] [Related]
2. CD133+/CD44+ prostate cancer stem cells exhibit embryo-like behavior patterns.
Acikgoz E; Soner BC; Ozdil B; Guven M
Acta Histochem; 2021 Jul; 123(5):151743. PubMed ID: 34157581
[TBL] [Abstract][Full Text] [Related]
3. WNT1 gene expression alters in heterogeneous population of prostate cancer cells; decreased expression pattern observed in CD133+/CD44+ prostate cancer stem cell spheroids.
Goksel G; Bilir A; Uslu R; Akbulut H; Guven U; Oktem G
J BUON; 2014; 19(1):207-14. PubMed ID: 24659666
[TBL] [Abstract][Full Text] [Related]
4. Cancer stem cell differentiation: TGFβ1 and versican may trigger molecules for the organization of tumor spheroids.
Oktem G; Sercan O; Guven U; Uslu R; Uysal A; Goksel G; Ayla S; Bilir A
Oncol Rep; 2014 Aug; 32(2):641-9. PubMed ID: 24927163
[TBL] [Abstract][Full Text] [Related]
5. Sonic hedgehog signaling is associated with resistance to zoledronic acid in CD133high/CD44high prostate cancer stem cells.
Acikgoz E; Mukhtarova G; Alpay A; Avci CB; Bagca BG; Oktem G
Mol Biol Rep; 2021 Apr; 48(4):3567-3578. PubMed ID: 33948856
[TBL] [Abstract][Full Text] [Related]
6. Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2.
Keysar SB; Le PN; Miller B; Jackson BC; Eagles JR; Nieto C; Kim J; Tang B; Glogowska MJ; Morton JJ; Padilla-Just N; Gomez K; Warnock E; Reisinger J; Arcaroli JJ; Messersmith WA; Wakefield LM; Gao D; Tan AC; Serracino H; Vasiliou V; Roop DR; Wang XJ; Jimeno A
J Natl Cancer Inst; 2017 Jan; 109(1):. PubMed ID: 27634934
[TBL] [Abstract][Full Text] [Related]
7. Characterization of CD133
Güler G; Guven U; Oktem G
Analyst; 2019 Mar; 144(6):2138-2149. PubMed ID: 30742170
[TBL] [Abstract][Full Text] [Related]
8. CD133 suppression increases the sensitivity of prostate cancer cells to paclitaxel.
Aghajani M; Mokhtarzadeh A; Aghebati-Maleki L; Mansoori B; Mohammadi A; Safaei S; Asadzadeh Z; Hajiasgharzadeh K; Khaze Shahgoli V; Baradaran B
Mol Biol Rep; 2020 May; 47(5):3691-3703. PubMed ID: 32246247
[TBL] [Abstract][Full Text] [Related]
9. Proteomic analysis of mTOR inhibition-mediated phosphorylation changes in ribosomal proteins and eukaryotic translation initiation factors.
Jiang X; Feng S; Chen Y; Feng Y; Deng H
Protein Cell; 2016 Jul; 7(7):533-7. PubMed ID: 27278278
[No Abstract] [Full Text] [Related]
10. HIF1α Regulates mTOR Signaling and Viability of Prostate Cancer Stem Cells.
Marhold M; Tomasich E; El-Gazzar A; Heller G; Spittler A; Horvat R; Krainer M; Horak P
Mol Cancer Res; 2015 Mar; 13(3):556-64. PubMed ID: 25349289
[TBL] [Abstract][Full Text] [Related]
11. Proteins of the Wnt signaling pathway as targets for the regulation of CD133+ cancer stem cells in glioblastoma.
Shevchenko V; Arnotskaya N; Korneyko M; Zaytsev S; Khotimchenko Y; Sharma H; Bryukhovetskiy I
Oncol Rep; 2019 May; 41(5):3080-3088. PubMed ID: 30864699
[TBL] [Abstract][Full Text] [Related]
12. miR-199a-3p targets stemness-related and mitogenic signaling pathways to suppress the expansion and tumorigenic capabilities of prostate cancer stem cells.
Liu R; Liu C; Zhang D; Liu B; Chen X; Rycaj K; Jeter C; Calhoun-Davis T; Li Y; Yang T; Wang J; Tang DG
Oncotarget; 2016 Aug; 7(35):56628-56642. PubMed ID: 27447749
[TBL] [Abstract][Full Text] [Related]
13. Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial-mesenchymal transition in squamous cell carcinoma.
Geng S; Guo Y; Wang Q; Li L; Wang J
Arch Dermatol Res; 2013 Jan; 305(1):35-47. PubMed ID: 22740085
[TBL] [Abstract][Full Text] [Related]
14. In vitro characterization of CD133
Nair RM; Balla MM; Khan I; Kalathur RKR; Kondaiah P; Vemuganti GK
BMC Cancer; 2017 Nov; 17(1):779. PubMed ID: 29162051
[TBL] [Abstract][Full Text] [Related]
15. CD44/CD133-Positive Colorectal Cancer Stem Cells are Sensitive to Trifluridine Exposure.
Tsunekuni K; Konno M; Haraguchi N; Koseki J; Asai A; Matsuoka K; Kobunai T; Takechi T; Doki Y; Mori M; Ishii H
Sci Rep; 2019 Oct; 9(1):14861. PubMed ID: 31619711
[TBL] [Abstract][Full Text] [Related]
16. A liaison between mTOR signaling, ribosome biogenesis and cancer.
Gentilella A; Kozma SC; Thomas G
Biochim Biophys Acta; 2015 Jul; 1849(7):812-20. PubMed ID: 25735853
[TBL] [Abstract][Full Text] [Related]
17. Co-Expression of Putative Cancer Stem Cell Markers CD44 and CD133 in Prostate Carcinomas.
Kalantari E; Asgari M; Nikpanah S; Salarieh N; Asadi Lari MH; Madjd Z
Pathol Oncol Res; 2017 Oct; 23(4):793-802. PubMed ID: 28083789
[TBL] [Abstract][Full Text] [Related]
18. Human non-small cell lung cancer expresses putative cancer stem cell markers and exhibits the transcriptomic profile of multipotent cells.
Zakaria N; Yusoff NM; Zakaria Z; Lim MN; Baharuddin PJ; Fakiruddin KS; Yahaya B
BMC Cancer; 2015 Feb; 15():84. PubMed ID: 25881239
[TBL] [Abstract][Full Text] [Related]
19. Dual-Blocking of PI3K and mTOR Improves Chemotherapeutic Effects on SW620 Human Colorectal Cancer Stem Cells by Inducing Differentiation.
Kim MJ; Koo JE; Han GY; Kim B; Lee YS; Ahn C; Kim CW
J Korean Med Sci; 2016 Mar; 31(3):360-70. PubMed ID: 26955235
[TBL] [Abstract][Full Text] [Related]
20. Gamma-Secretase Inhibitor IX (GSI) Impairs Concomitant Activation of Notch and Wnt-Beta-Catenin Pathways in CD44
Barat S; Chen X; Cuong Bui K; Bozko P; Götze J; Christgen M; Krech T; Malek NP; Plentz RR
Stem Cells Transl Med; 2017 Mar; 6(3):819-829. PubMed ID: 28186678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
